Home › Mantle Cell Lymphoma › Texas
Pag-aaral pangklinika para sa Mantle Cell Lymphoma sa Texas
19 pag-aaral para sa Mantle Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa Texas.
Mga Lungsod sa Texas
Opisyal na teksto ng pag-aaral (English)
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Houston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06542250A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Md Anderson Cancer Center, Houston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05006716A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Md Anderson Cancer Center, Houston
- Texas Oncology Austin Midtown, Round Rock
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06742996A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Texas Southwestern, Dallas
- MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07101328A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Houston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06564038Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- The University of TX MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 30, 2026 · NCT07424833DALY II USA/ MB-CART2019.1 for DLBCL
- UT Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- Texas Transplant Institute, San Antonio
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
- M D Anderson Cancer Center, Houston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT05529069Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
- MD Anderson Cancer Center, Houston
Nagre-recruitPhase 2Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 23, 2026 · NCT06263491The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
Nagre-recruitPhase 1/2
Edad 12 hanggang 95 · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 20, 2026 · NCT04830137Study of SGR-1505 in Mature B-Cell Neoplasms
- University of Texas Southwestern, Dallas
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT05544019AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 10, 2025 · NCT05602363A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- SCRI, San Antonio
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 14, 2025 · NCT05643742SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of Texas Southwestern Medical Center, Dallas
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2025 · NCT05780034Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- M D Anderson Cancer Center, Houston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 18, 2024 · NCT05910801Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.